Lessons from ECLIPSE: A review of COPD biomarkers

Thorax

Volumn 69, Issue 7, 2014, Pages 666-672

  Faner, Rosa ^a   Tal Singer, Ruth ^b   Riley, John H ^c   Celli, Bartolomé ^d   Vestbo, Jørgen ^e,f   MacNee, William ^g   Bakke, Per ^h   Calverley, Peter M A ⁱ   Coxson, Harvey ^j   Crim, Courtney ^b   Edwards, Lisa D ^b   Locantore, Nick ^b   Lomas, David A ^k   Miller, Bruce E ^b   Rennard, Stephen I ^l   Wouters, Emiel F M ^m   Yates, Julie C ^b   Silverman, Edwin K ^d   Agusti, Alvar ^a,n  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

^b GLAXOSMITHKLINE   (United States)

^c GLAXOSMITHKLINE   (United Kingdom)

^d HARVARD MEDICAL SCHOOL   (United States)

^e ODENSE UNIVERSITY HOSPITAL   (Denmark)

^f UNIVERSITY OF MANCHESTER   (United Kingdom)

^g UNIVERSITY OF EDINBURGH   (United Kingdom)

^h UNIVERSITY OF BERGEN   (Norway)

ⁱ UNIVERSITY HOSPITAL AINTREE   (United Kingdom)

^j UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^k UNIVERSITY COLLEGE LONDON   (United Kingdom)

^l UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^m MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

ⁿ HOSPITAL CLÍNIC   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; C REACTIVE PROTEIN; CORTICOSTEROID; FIBRINOGEN; INTERLEUKIN 6; INTERLEUKIN 8; TUMOR NECROSIS FACTOR ALPHA; VITAMIN D;

CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL PRACTICE; DIAGNOSTIC ACCURACY; DISEASE EXACERBATION; DISEASE MARKER; DISEASE PREDISPOSITION; EMPHYSEMA; EXHALED BREATH CONDENSATE; FORCED EXPIRATORY VOLUME; GENE IDENTIFICATION; GENETIC ASSOCIATION; GENETIC MARKER; GENETIC SUSCEPTIBILITY; HEREDITY; HUMAN; IMMUNOASSAY; INTERNATIONAL COOPERATION; LEUKOCYTE COUNT; MULTICENTER STUDY (TOPIC); NEUTROPHIL COUNT; NEUTROPHILIA; OBSERVATIONAL STUDY; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN DETERMINATION; REVIEW; SMOKING; SPUTUM EXAMINATION; TRANSCRIPTOMICS;

EMPHYSEMA;

BIOLOGICAL MARKERS; HUMANS; LONGITUDINAL STUDIES; PREDICTIVE VALUE OF TESTS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SEVERITY OF ILLNESS INDEX;

EID: 84902164334     PISSN: 00406376     EISSN: 14683296     Source Type: Journal    
DOI: 10.1136/thoraxjnl-2013-204778     Document Type: Review

References (59)

1. Vestbo J, Anderson W, Coxson HO, et al. Evaluation of COPD Longitudinally to Identify Predictive Surrogate End-points (ECLIPSE). Eur Respir J 2008;31:869-73.
2. Stanescu D, Sanna A, Veriter C, et al. Airways obstruction, chronic expectoration, and rapid decline of FEV1 in smokers are associated with increased levels of sputum neutrophils. Thorax 1996;51:267-71. (Pubitemid 26086470)
3. Singh D, Edwards L, Tal-Singer R, et al . Sputum neutrophils as a biomarker in COPD: findings from the ECLIPSE study. Respir Res 2010;11:77.
4. Agusti A, Edwards LD, Rennard SI, et al. Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotype. PLoS ONE 2012;7:e37483.
5. Hurst JR, Vestbo J, Anzueto A, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 2010;363:1128-38.
6. Celli BR, Locantore N, Yates J, et al. Inflammatory biomarkers improve clinical prediction of mortality in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2012;185:1065-72.
7. Thomsen M, Ingebrigtsen TS, Marott JL, et al. Inflammatory biomarkers and exacerbations in chronic obstructive pulmonary disease. JAMA 2013;309:2353-61.
8. Pinto-Plata V, Toso J, Lee K, et al. Profiling serum biomarkers in patients with COPD: associations with clinical parameters. Thorax 2007;62:595-601. (Pubitemid 47056886)
9. Dickens JA, Miller BE, Edwards LD, et al. COPD association and repeatability of blood biomarkers in the ECLIPSE cohort. Respir Res 2011;12:146.
10. Duvoix A, Dickens J, Haq I, et al. Blood fibrinogen as a biomarker of chronic obstructive pulmonary disease. Thorax 2013;68:670-6.
11. Casaburi R, Celli B, Crapo J, et al. The COPD Biomarker Qualification Consortium (CBQC). COPD 2013;10:367-77.
12. Lomas DA, Silverman EK, Edwards LD, et al. Evaluation of serum CC-16 as a biomarker for COPD in the ECLIPSE cohort. Thorax 2008;63:1058-63.
13. Vestbo J, Edwards LD, Scanlon PD, et al. Changes in forced expiratory volume in 1 second over time in COPD. N Engl J Med 2011;365:1184-92.
14. Coxson HO, Dirksen A, Edwards L, et al. Change in lung density measured using computed tomography in chronic obstructive pulmonary disease. Lancet Respir (In press 2013).
15. Hanania NA, Mullerova H, Locantore NW, et al. Determinants of depression in the ECLIPSE chronic obstructive pulmonary disease cohort. Am J Respir Crit Care Med 2011;183:604-11.
16. Lomas DA, Silverman EK, Edwards LD, et al. Serum surfactant protein D is steroid sensitive and associated with exacerbations of COPD. Eur Respir J 2009;34:95-102.
17. Sin DD, Miller BE, Duvoix A, et al. Serum PARC/CCL-18 concentrations and health outcomes in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2011;183:1187-92.
18. Miller J, Edwards LD, Agusti A, et al. Comorbidity, systemic in flammation and outcomes in the ECLIPSE cohort. Respir Med 2013;107:1376-84.
19. Rutten EP, Breyer MK, Spruit MA, et al. Abdominal fat mass contributes to the systemic inflammation in chronic obstructive pulmonary disease. Clin Nutr 2010;29:756-60.
20. Breyer MK, Rutten EP, Locantore NW, et al. Dysregulated adipokine metabolism in chronic obstructive pulmonary disease. Eur J Clin Invest 2012;42:983-91.
21. Berg I, Hanson C, Sayles H, et al. Vitamin D, vitamin D binding protein, lung function and structure in COPD. Respir Med 2013;107:1578-88.
22. Cheng DT, Kim DK, Cockayne DA, et al. Systemic sRAGE is a biomarker of emphysema and associated with AGER genetic variants in COPD patients. Am J Respir Crit Care Med 2013;188:948-57.
23. Bakke PS, Zhu G, Gulsvik A, et al. Candidate genes for COPD in two large data sets. Eur Respir J 2011;37:255-63.
24. Zhu G, Warren L, Aponte J, et al. The SERPINE2 gene is associated with chronic obstructive pulmonary disease in two large populations. Am J Respir Crit Care Med 2007;176:167-73. (Pubitemid 47057853)
25. National Emphysema Treatment Trial Research Group. A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema. N Engl J Med 2003;348:2059-73.
26. Litonjua AA, Lazarus R, Sparrow D, et al. Lung function in type 2 diabetes: the Normative Aging Study. Respir Med 2005;99:1583-90. (Pubitemid 41683939)
27. Anthonisen NR, Connett JE, Kiley JP, et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1 . The Lung Health Study. JAMA 1994;272:1497-505.
28. Regan EA, Hokanson JE, Murphy JR, et al . Genetic epidemiology of COPD (COPDGene) study design. COPD: J Chron Obstruct Pulmon Dis 2010;7:32-43.
29. Vestbo J, Hurd SS, Agusti AG, et al. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease: GOLD Executive Summary. Am J Respir Crit Care Med 2013;187:347-65.
30. Siedlinski M, Cho MH, Bakke P, et al. Genome-wide association study of smoking behaviours in patients with COPD. Thorax 2011;66:894-902.
31. 25-75/FVC in families with severe, early onset COPD. Thorax 2004;59:396-400.
32. Cho MH, Boutaoui N, Klanderman BJ, et al. Variants in FAM13A are associated with chronic obstructive pulmonary disease. Nat Genet 2010;42:200-2.
33. Cho MH, Castaldi PJ, Wan ES, et al. A genome-wide association study of COPD identifies a susceptibility locus on chromosome 19q13. Hum Mol Genet 2012;21:947-57.
34. Thorgeirsson TE, Gudbjartsson DF, Surakka I, et al. Sequence variants at CHRNB3-CHRNA6 and CYP2A6 affect smoking behavior. Nat Genet 2010;42:448-53.
35. Hancock DB, Eijgelsheim M, Wilk JB, et al. Meta-analyses of genome-wide association studies identify multiple loci associated with pulmonary function. Nat Genet 2010;42:45-52.
36. Repapi E, Sayers I, Wain LV, et al. Genome-wide association study identifies five loci associated with lung function. Nat Genet 2010;42:36-44.
37. Castaldi PJ, Cho MH, Litonjua AA, et al. The association of genome-wide significant spirometric loci with chronic obstructive pulmonary disease susceptibility. Am J Respir Cell Mol Biol 2011;45:1147-53.
38. Foreman MG, Kong X, DeMeo DL, et al. Polymorphisms in surfactant protein-D are associated with chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol 2011;44:316-22.
39. Jiang H, Orr A, Guernsey DL, et al. Application of homozygosity haplotype analysis to genetic mapping with high-density SNP genotype data. PLoS ONE 2009;4:e5280.
40. Brehm JM, Hagiwara K, Tesfaigzi Y, et al. Identification of FGF7 as a novel susceptibility locus for chronic obstructive pulmonary disease. Thorax 2011;66:1085-90.
41. Siedlinski M, Tingley D, Lipman PJ, et al. Dissecting direct and indirect genetic effects on chronic obstructive pulmonary disease (COPD) susceptibility. Hum Genet 2013;132:431-41.
42. Pillai SG, Kong X, Edwards LD, et al. Loci identified by genome-wide association studies in fluence different disease-related phenotypes in COPD. Am J Respir Crit Care Med 2010;182:1498-505.
43. Kong X, Cho MH, Anderson W, et al. Genome-wide association study identifies BICD1 as a susceptibility gene for emphysema. Am J Respir Crit Care Med 2011;183:43-9.
44. Faner R, Rojas M, MacNee W, et al. Abnormal lung aging in chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2012;186:306-13.
45. Schols AM, Broekhuizen R, Weling-Scheepers CA, et al. Body composition and mortality in chronic obstructive pulmonary disease. Am J Clin Nutr 2005;82:53-9. (Pubitemid 41716377)
46. Wan ES, Cho MH, Boutaoui N, et al. Genome-wide association analysis of body mass in chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol 2011;45:304-10.
47. Kim DK, Cho MH, Hersh CP, et al. Genome-wide association analysis of blood biomarkers in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2012;186:1238-47.
48. Singh D, Fox SM, Tal-Singer R, et al. Induced sputum genes associated with spirometric and radiological disease severity in COPD ex-smokers. Thorax 2011;66:489-95.
49. Imaoka H, Hoshino T, Takei S, et al. IL-18 production and pulmonary function in chronic obstructive pulmonary disease. Eur Respir J 2008;31:287-97.
50. Kang MJ, Choi JM, Kim BH, et al. IL-18 induces emphysema and airway and vascular remodeling via IFNgamma, IL-17A, and IL-13. Am J Respir Crit Care Med 2012;185:1205-17.
51. Qiu W, Cho MH, Riley JH, et al. Genetics of sputum gene expression in chronic obstructive pulmonary disease. PLoS ONE 2011;6:e24395.
52. Ubhi BK, Riley JH, Shaw PA, et al. Metabolic profiling detects biomarkers of protein degradation in COPD patients. Eur Respir J 2012;40:345-55.
53. Ubhi BK, Cheng KK, Dong J, et al. Targeted metabolomics identifies perturbations in amino acid metabolism that sub-classify patients with COPD. Mol Biosyst 2012;8:3125-33.
54. MacNee W, Rennard SI, Hunt JF, et al. Evaluation of exhaled breath condensate pH as a biomarker for COPD. Respir Med 2011;105:1037-45.
55. Esther CR Jr, Lazaar AL, Bordonali E, et al. Elevated airway purines in COPD. Chest 2011;140:954-60.
56. Basanta M, Jarvis RM, Xu Y, et al. Non-invasive metabolomic analysis of breath using differential mobility spectrometry in patients with chronic obstructive pulmonary disease and healthy smokers. Analyst 2010;135:315-20.
57. Barabasi AL, Gulbahce N, Loscalzo J. Network medicine: a network-based approach to human disease. Nat Rev Genet 2011;12:56-68.
58. Menche J, Sharma A, Cho MH, et al. Development of a novel superVIsed Shuffling Approach (VIStA) to identify complex disease subtypes using gene expression data and application to chronic obstructive pulmonary disease. Mol Syst Biol (In press 2013).
59. Rennard SI, Vestbo J, Silverman EK, et al. Determination of COPD characteristics via unsupervised clustering on the ECLIPSE cohort. Eur Respir J 2011;38(Suppl 55):762s.